UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~November~~January 1211, ~~2025~~2026

IDEXX LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-19271	01-0393723
(State or other jurisdiction	(Commission File Number)	(IRS Employer Identification No.)
of incorporation)

One IDEXX Drive, Westbrook, Maine	04092
(Address of principal executive offices)	(ZIP Code)

207.556.0300

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.10 par value per share		IDXX		NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 15.0102. ~~Entry~~Departure ~~into~~of aDirectors ~~Material~~or ~~Definitive~~Certain ~~Agreement~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

~~Amendment~~CEO NoTransition. ~~2 to Fourth Amended and Restated Credit Agreement~~

On ~~November~~January 11, 122026, ~~2025,~~Jonathan (Jay) Mazelsky notified IDEXX Laboratories, Inc. (the “Company”), ~~with~~or “IDEXX”) ~~Distribution, Inc.,~~of ~~IDEXX~~his ~~Operations,~~intent ~~Inc.,~~to ~~OPTI~~step down ~~Medical~~as ~~Systems,~~the ~~Inc.,~~Company’s ~~IDEXX~~President ~~Laboratories~~and ~~Canada~~Chief ~~Corporation,~~Executive ~~IDEXX~~Officer ~~B.V.,~~effective ~~IDEXX~~as ~~Laboratories B.V.~~of May 12, ~~IDEXX~~2026 ~~Laboratories~~(the ~~GmbH,~~“Transition Date”) and ~~IDEXX~~retire ~~Holdings~~from IIthe ~~GmbH,~~Company ~~each~~and athe ~~wholly-owned~~Company’s ~~subsidiary~~Board ~~(whether directly or indirectly held)~~ of the ~~Company~~Directors (~~collectively,~~ the “~~Borrowers~~Board”), ~~together~~immediately ~~with~~following the ~~lenders identified on the signature pages thereto,~~Company’s ~~JPMorgan~~annual ~~Chase~~meeting ~~Bank,~~of ~~N.A.,~~shareholders asin ~~administrative~~May 2027 ~~agent~~ (the “~~Agent~~Retirement Date”),. ~~and the~~On ~~other~~January 13, ~~parties thereto~~2026, ~~entered~~the ~~into~~Company ~~Amendment~~announced ~~No. 2 (the “Amendment”),~~that toeffective ~~that~~as ~~certain~~of ~~fourth~~the ~~amended~~Transition ~~and~~Date ~~restated~~Mr. Mazelsky ~~credit~~will ~~agreement~~transition ~~relating~~ to athe ~~five-year~~role ~~unsecured~~of ~~revolving~~Executive ~~credit~~Chair ~~facility~~of in the ~~principal~~ ~~amount~~Board ofand ~~$1.0 billion~~Michael (asMike) ~~amended~~Erickson, PhD, bywill ~~that~~assume ~~certain~~the ~~Amendment~~role ~~No. 1 dated as~~ of ~~October~~President ~~20,~~and ~~2022~~Chief ~~relating~~Executive toOfficer ~~a three-year~~of ~~unsecured~~the ~~term~~Company ~~loan~~and injoin the ~~principal~~Board ~~amount~~as ofa ~~$250~~Class ~~million,~~II ~~the~~Director. ~~“Existing Credit~~In ~~Agreement”,~~his ~~and~~ capacity as ~~amended~~President byand ~~the~~Chief ~~Amendment~~Executive Officer, ~~the~~Dr. Erickson ~~“Credit Agreement”),~~will ~~among~~serve as the ~~Borrowers,~~Company’s ~~the~~principal ~~lenders,~~executive ~~the~~officer. ~~Agent,~~Mr. Mazelsky will ~~JPMorgan~~work ~~Chase~~closely ~~Bank,~~with NDr.~~A.,~~ Erickson ~~Toronto~~until ~~Branch,~~Mr. Mazelsky’s asRetirement ~~Toronto~~Date ~~Agent, and~~to ~~the~~support ~~other~~a ~~parties~~seamless ~~thereto~~transition. ~~Capitalized~~Mr. Lawrence D. ~~terms~~Kingsley, ~~not~~currently ~~otherwise~~serving ~~defined~~as ~~herein~~the ~~shall~~Board’s ~~have~~independent ~~the~~Non-Executive ~~meanings~~Chair, ~~ascribed~~will toserve ~~such~~as ~~terms~~independent inLead ~~the~~Director effective ~~Credit~~as ~~Agreement~~of the Transition Date.

~~The~~Dr. Erickson, ~~Amendment~~52, ~~amends~~brings ~~the~~nearly ~~Existing~~two ~~Credit~~decades ~~Agreement~~of toleadership ~~(i) provide~~experience ~~for~~and asignificant ~~term~~healthcare ~~loan~~technology ~~facility maturing three years from the closing date of the Amendment~~ and ~~extending~~innovation ~~the~~expertise. ~~maturity~~Since ~~date~~joining ~~with~~IDEXX ~~respect~~in ~~to the revolving credit facility to five years from the closing date of the Amendment~~2011, ~~(ii) provide~~ ~~for~~he ~~IDEXX~~has ~~Holdings~~held IIsenior ~~GmbH~~positions toacross ~~assume~~key ~~all~~portions ~~the~~of ~~rights and Obligations under~~ the ~~Loan~~Company’s ~~Documents~~business, ofincluding adiagnostics, ~~“Borrower”~~software, ~~under~~strategy and ascorporate ~~defined in the Credit Agreement~~accounts, ~~(iii)~~and ~~make~~currently ~~certain~~serves ~~other~~as ~~amendments~~Executive toVice ~~the~~President ~~Existing Credit Agreement,~~ and ~~(iv) add~~General ~~certain~~Manager ~~implementing mechanics~~of ~~relating~~IDEXX’s toGlobal ~~the~~Point ~~foregoing.~~of ~~Under~~Care ~~the~~Diagnostics ~~Credit~~and ~~Agreement, there remains an unsecured revolving credit facility in the principal~~Telemedicine ~~amount~~lines of $1business.~~0 billion,~~ anPrior ~~unsecured~~to ~~term~~joining ~~loan in~~ the ~~principal~~Company, ~~amount~~Dr. Erickson ofadvised ~~$250~~leading ~~million~~pharmaceutical, biotechnology and ~~flexibility~~health toservice ~~incur incremental revolving~~companies ~~credit~~as ~~commitments~~an ~~and/or~~Associate ~~term~~Principal ~~loans~~at inMcKinsey & ~~the aggregate principal amount of up to $250 million~~Company.

~~Borrowings under~~There ~~the~~are Credit Agreement may be used for the general corporate purposes of the Company and its subsidiaries. After giving effect to the Amendment, borrowings under the Credit Agreement bear interest at a rate equal to, in each case at the Company’s option, (1) for borrowings in United States Dollars, either (a) a base rate, determined as the greatest of (i) the Prime Rate, (ii) the NYFRB Rate plus 0.50% and (iii) the Adjusted Term SOFR Rate for a one-month Interest Period plus 1% (but no ~~less than 1%)~~arrangements ~~plus~~or aunderstandings ~~margin~~between ~~ranging from 0~~Dr.~~0% to 0.375% based on the Company’s consolidated leverage ratio, (b)~~ anErickson ~~adjusted~~and ~~Term~~any ~~SOFR~~other ~~Rate determined~~persons aspursuant ~~the applicable rate published by CME Group Benchmark Administration Limited (or a successor thereto) as of 5:00 a.m. Chicago time two U.S. Government Securities Business Days prior~~ to ~~the~~which ~~commencement~~he ofwill ~~the~~be ~~applicable~~appointed ~~Interest Period, plus 0.10%, plus a margin rate ranging from 0.875%~~ to ~~1.375%~~serve ~~based~~as on the Company’s ~~consolidated leverage ratio, or (c) an adjusted Daily Simple SOFR~~ ~~Rate~~President ~~determined~~and asChief ~~the~~Executive applicable secured overnight financing rate administered by the Federal Reserve Bank of New York (or a successor thereto) for the day that is five RFR Business Days prior to the subject rate selection date (or the RFR Business Day immediately preceding the subject date, in the case where the subject date is not a RFR Business Day), plus a margin rate ranging from 0Officer.~~875%~~ ~~to 1~~Dr.~~375% based on the Company’s consolidated leverage ratio, (2)~~ ~~for~~Erickson ~~borrowings~~has ~~in Canadian Dollars, either (a) a base rate equal to the PRIMCAN Index rate that appears on the Bloomberg screen at 10:15 a.m. Toronto time on the Quotation Day plus 1% (but~~ no ~~less~~direct than 1%), plus a margin ranging from 0.0% to 0.375% based on the Company’s consolidated leverage ratio (which rate shall be available for swingline borrowings only), (b) an adjusted Term CORRA Rate as determined by the Term CORRA Administrator (or aindirect ~~successor thereto)~~material ~~as of 1:00 p.m. Toronto time the day that is two Business Days prior to the first day of such Interest Period, plus (i) 0.29547% for a one month~~ interest period or (ii) 0.32138% for a three month interest period, and (c) following a Benchmark Transition Event or Benchmark Replacement Date, an adjusted Daily Simple CORRA determined by the CORRA Administrator on the CORRA Administrator’s website (or a successor thereto) for the day that is five RFR Business Days prior to (i) if such CORRA Rate Day is an RFR Business Day, such CORRA Rate Day or (ii) if such CORRA Rate Day is not an RFR Business Day, the RFR Business Day immediately preceding such CORRA Rate Day, in ~~each~~ ~~case,~~any astransaction ~~such~~required ~~CORRA is published by the CORRA Administrator on the CORRA Administrator’s website, plus a margin rate ranging from 0.875%~~ to ~~1.375% based on the Company’s consolidated leverage ratio, (3) for borrowings in Euros, the percentage per annum~~be ~~displayed~~disclosed onpursuant ~~the EURIBOR or other applicable page of the Thomson Reuters screen, multiplied by a statutory reserve rate, plus a margin rate ranging from 0.875%~~ to ~~1.375%~~Item ~~based on the Company’s consolidated leverage ratio,~~ 404(4a) for borrowings in Australian Dollars, the average bid rate on Thomson Reuters Screen BBSY Page at approximately 11:00 a.m. Sydney, Australia time, on the date that is two Business Days prior to the first day of ~~such~~Regulation ~~Interest Period for bills of exchange having a term equal to the length of such Interest Period~~S-K, ~~multiplied by a statutory reserve rate, plus a margin rate ranging from 0.875% to 1.375% based on the Company’s consolidated leverage ratio~~ and ~~(5)~~Dr. ~~for~~Erickson ~~borrowings~~has inno ~~alternative~~family ~~currencies~~relationships ~~(other~~with ~~than~~any ~~United~~director ~~States~~or ~~Dollars, Canadian Dollars, Euros and Australian Dollars),~~executive ~~the~~officer ~~Daily Simple RFR determined by the Agent for such currency in accordance with the terms~~ of the ~~Credit Agreement~~Company.

~~The~~Erickson ~~Company~~Letter ~~has also agreed to pay certain other fees, costs and expenses to the Agent and lenders in connection with the Amendment~~Agreement.

~~The~~On ~~obligations~~January 12, ~~of the~~2026, ~~Borrowers~~in ~~and~~connection ~~any~~with ~~other~~Dr. Erickson’s ~~parties~~anticipated ~~who~~appointment ~~are~~as ~~subsequently~~President ~~designated~~and asChief ~~borrowers~~Executive ~~pursuant~~Officer tocommencing on the ~~terms~~Transition Date, ofDr. Erickson entered into a letter agreement (the ~~Credit~~“Erickson Letter Agreement”) ~~are~~with ~~unconditionally guaranteed~~the byCompany. ~~IDEXX~~The ~~Distribution,~~Erickson ~~Inc.,~~Letter Agreement ~~IDEXX~~sets ~~Operations,~~forth ~~Inc.~~the terms and ~~OPTI~~conditions ~~Medical~~of ~~Systems, Inc~~Dr. Erickson’s Ifemployment ~~the~~as ~~Company~~President ~~creates~~and orChief ~~acquires~~Executive aOfficer ~~material~~and further ~~U.S.~~provides ~~subsidiary,~~that orDr. Erickson ifwill ~~any~~be ~~existing~~appointed ~~U.S.~~to ~~subsidiary~~the ~~becomes~~Board aas ~~material~~of ~~subsidiary,~~the ~~each~~Transition ~~such~~Date ~~material~~and ~~U.S.~~thereafter ~~subsidiary~~ will be ~~required~~nominated by the Board tofor ~~execute~~reelection aduring ~~guaranty~~his ~~agreement~~employment as President and Chief Executive Officer.

~~The~~Under ~~obligations~~the terms of the Erickson ~~Company~~Letter ~~and~~Agreement, ~~any~~Dr. Erickson ~~other~~will ~~borrower~~receive ~~under~~an ~~the~~annualized ~~Credit~~base ~~Agreement~~salary ~~may~~of be$1,000,000 ~~accelerated~~and ~~upon~~an ~~the~~annual ~~occurrence~~bonus with a target of an120% ~~event~~of base salary, effective as of ~~default~~the ~~under~~Transition Date. With respect to the ~~Credit Agreement~~Company’s 2026 fiscal year, ~~which~~Dr. Erickson ~~includes~~is ~~customary~~expected to ~~events~~receive a long-term incentive equity award with a target grant date value of ~~default~~not ~~including,~~less ~~without~~than ~~limitation~~$7.8 million, ~~payment~~to ~~defaults,~~be ~~defaults~~granted in the ~~performance of~~form ~~affirmative~~of stock options (50%) and ~~negative~~performance ~~covenants~~restricted stock units (50%), under the ~~inaccuracy~~Company’s of2018 ~~representations~~Stock orIncentive ~~warranties~~Plan (as amended, restated, ~~bankruptcy~~amended and ~~insolvency~~restated ~~related~~or ~~defaults,~~replaced ~~defaults relating~~from time to ~~judgments~~time, anthe ~~ERISA~~“Incentive ~~Event~~Plan”), as part of the ~~failure~~Company’s annual equity award cycle in February 2026. With respect to ~~pay~~the ~~specified~~Company’s ~~indebtedness~~2027 fiscal year and each year thereafter during his employment as President and Chief Executive Officer, Dr. Erickson will be eligible to receive equity awards under the Incentive Plan, with grant date values and aterms ~~change~~and conditions as determined by the Compensation and Talent Committee of ~~control~~the ~~default~~Board from time to time.

~~The~~If ~~Credit Agreement~~Dr. Erickson’s ~~contains~~employment ~~affirmative,~~is ~~negative~~terminated ~~and~~by ~~financial~~the ~~covenants~~Company ~~customary~~following ~~for~~the ~~financings~~Transition ofDate ~~this~~without ~~type.~~“Cause” ~~The~~(as ~~negative~~defined ~~covenants~~therein), ~~include~~other ~~restrictions~~than under onthe ~~liens,~~terms ~~indebtedness~~ of ~~subsidiaries~~the ofErickson ~~the~~CIC ~~Company,~~Agreement ~~fundamental~~(as ~~changes,~~defined ~~investments~~and described below), ~~transactions~~the ~~with~~Erickson ~~affiliates,~~Letter ~~certain~~Agreement ~~restrictive~~provides that Dr. Erickson ~~agreements~~will ~~and~~be ~~violations~~entitled ofto ~~sanctions~~receive ~~laws~~the ~~and~~following, ~~regulations.~~subject ~~The~~to ~~financial~~execution ~~covenant~~and isnon-revocation of a ~~consolidated~~release ~~leverage~~of ~~ratio~~claims ~~test.~~and continued compliance with the applicable restrictive covenants:

~~The~~· ~~foregoing description~~Salary continuation for two years following termination of ~~the~~employment; ~~Amendment~~· ~~and~~A lump-sum payment of the ~~Credit~~employer ~~Agreement~~portion ~~does~~of ~~not~~the ~~purport~~cost toof becontinued ~~complete~~health ~~and~~benefits isfor ~~subject~~Dr. ~~to,~~Erickson and ~~qualified~~covered independents ~~its~~for ~~entirety by,~~such ~~the~~two-year ~~full~~period; ~~text~~and · Continued vesting of ~~the~~equity ~~Amendment~~incentive ~~(including~~awards ~~Annex~~for Itwo ~~thereto)~~years ~~and~~following ~~the~~termination ~~Credit~~of ~~Agreement~~employment, ~~which~~except ~~are~~as ~~filed~~may asbe ~~Exhibit~~otherwise ~~10.1~~provided ~~hereto~~under ~~and~~the ~~incorporated herein~~applicable byaward ~~reference~~agreements.

~~Item~~The ~~2.03~~Erickson Letter Agreement ~~Creation~~does not amend or supersede the terms of athe ~~Direct~~Confidential ~~Financial~~Information, ~~Obligation~~Work Product, and Restrictive Covenant Agreement, between Dr. Erickson and the Company, dated as of March 4, 2022, or anany ~~Obligation~~award agreements evidencing grants under anthe ~~Off-Balance~~Company’s ~~Sheet~~stock ~~Arrangement~~incentive ofplans to which Dr. Erickson is a ~~Registrant~~party.

ToA ~~the~~copy ~~extent required,~~of the ~~information~~Erickson ~~set~~Letter Agreement ~~forth~~is inincluded ~~Item~~as Exhibit 10.1 to this Current Report on Form 8-K.01 The description of the Erickson Letter Agreement included in this Current Report on Form 8-K is ~~incorporated~~a ~~into~~summary, ~~this~~is ~~Item~~not ~~2.03~~complete and is qualified in its entirety by reference to the terms of the Erickson Letter Agreement filed as Exhibit 10.1 hereto.

Erickson Amended and Restated CIC Agreement.

As an Executive Vice President, Dr. Erickson was a party to a change in control agreement that provided for certain benefits upon a qualifying termination of employment that follows a change in control of IDEXX. In connection with the CEO transition, Dr. Erickson entered into an amended and restated change in control agreement (the “Erickson CIC Agreement”) on January 12, 2026, to be effective on the Transition Date.

Under the Erickson CIC Agreement, if Dr. Erickson’s employment is terminated after the Transition Date by the Company without “Cause” or by Dr. Erickson with “Good Reason” within the two-year period following a “Change in Control” (as such terms are defined in the Erickson CIC Agreement) (a “Qualifying CIC Termination”), Dr. Erickson will be entitled to receive the following, subject to execution and non-revocation of a release of claims and continued compliance with the applicable restrictive covenants:

	·	A lump-sum payment of an amount equal to the sum of (i) earned but unpaid base salary, (ii) target bonus for the portion of the year prior to the Qualifying CIC Termination, and (iii) any compensation previously deferred by Dr. Erickson and any accrued vacation pay, in each case to the extent unpaid;
	·	A lump-sum payment of an amount equal to three times the sum of (i) Dr. Erickson’s annual base salary and (ii) the average bonus received by him for the three prior full fiscal years;
	·	Continuation of all benefits under welfare, benefit, savings and retirement plans for up to three years; and
	·	Reimbursement of up to $12,500 per year (an aggregate of $25,000) for expenses incurred in connection with outplacement services and relocation costs in connection with obtaining new employment.

In addition, the Erickson CIC Agreement provides that upon a Qualifying CIC Termination, all shares underlying Dr. Erickson’s outstanding equity awards subject only to time-based vesting conditions will become immediately exercisable or vested, as applicable. The terms of the performance-based equity awards will continue to be governed by the Incentive Plan and the applicable equity award agreements.

A copy of the Erickson CIC Agreement is included as Exhibit 10.2 to this Current Report on Form 8-K. The description of the Erickson CIC Agreement included in this Current Report on Form 8-K is a summary, is not complete and is qualified in its entirety by reference to the terms of the Erickson CIC Agreement filed as Exhibit 10.2 hereto.

Mazelsky Letter Agreement.

On January 12, 2026, Mr. Mazelsky entered into a letter agreement (the “Mazelsky Letter Agreement”) with the Company, which will become effective and supersede Mr. Mazelsky’s current employment agreement with the Company effective on the Transition Date. The Mazelsky Letter Agreement provides for the terms and conditions of his continued employment as Executive Chair from the Transition Date through the Retirement Date, unless terminated earlier by the Company or Mr. Mazelsky. The Mazelsky Letter Agreement provides that, in exchange for his service as Executive Chair, Mr. Mazelsky will be paid an annual base salary of $1,150,000 through the Retirement Date. In addition, with respect to the 2026 fiscal year, Mr. Mazelsky will be eligible for a target annual bonus opportunity determined as a percentage of the annual base salary actually paid with respect to the 2026 fiscal year equal to the blended rate of (i) 130% for the period from January 1 through the Transition Date and (ii) 100% for the period from the Transition Date through December 31, 2026 (the “FY 2026 Bonus”).

As part of the Company’s annual equity award cycle, it is expected that Mr. Mazelsky will receive a grant of time-vesting restricted stock units with a target grant date value of not less than $8.275 million in February 2026, which will serve as Mr. Mazelsky’s equity incentive compensation with respect to the Company’s 2026 fiscal year and with respect to the portion of the Company’s 2027 fiscal year prior to the Retirement Date. Mr. Mazelsky will not be eligible for any other cash or equity incentive payments with respect to his employment as Executive Chair during the 2027 fiscal year.

If Mr. Mazelsky’s employment with the Company is terminated by the Company after the Transition Date and prior to the Retirement Date without “Cause” (as defined in the Mazelsky Letter Agreement) (an “Involuntary Termination”), Mr. Mazelsky will be entitled to receive the following, subject to execution and non-revocation of a release of claims and continued compliance with the applicable restrictive covenants:

	·	A lump-sum payment of Mr. Mazelsky’s base salary through the Retirement Date; and
	·	FY 2026 Bonus (to the extent not already paid), calculated based on actual performance of the Company, payable at the same time such bonus is paid to other executive officers of the Company.

If the Involuntary Termination occurs on or prior to February 14, 2027, the Company will permit Mr. Mazelsky to take a personal unpaid leave through February 15, 2027, at which time Mr. Mazelsky will be deemed to retire and will be treated as experiencing a qualifying “retirement” for purposes of the applicable compensation and benefit plans and programs of the Company.

The Mazelsky Letter Agreement does not amend or supersede the terms of the Confidential Information, Work Product, and Restrictive Covenant Agreement, between Mr. Mazelsky and the Company, dated as of January 19, 2022, or any award agreements evidencing grants under the Company’s stock incentive plans to which Mr. Mazelsky is a party.

A copy of the Mazelsky Letter Agreement is included as Exhibit 10.3 to this Current Report on Form 8-K. The description of the Mazelsky Letter Agreement included in this Current Report on Form 8-K is a summary, is not complete and is qualified in its entirety by reference to the terms of the Mazelsky Letter Agreement filed as Exhibit 10.3 hereto.

Item 7.01. Regulation FD Disclosure.

A copy of the press release dated January 13, 2026, announcing these matters is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.		Description of Document
10.1	Letter Agreement by and between Michael (Mike) Erickson, PhD, and IDEXX Laboratories, Inc., dated January 12, 2026.
10.1		Amendment No. 2 to the Fourth Amended and Restated Credit Agreement, dated as of November 12, 2025, by and among the Company, IDEXX Distribution, Inc., IDEXX Operations, Inc., OPTI Medical Systems, Inc., IDEXX Laboratories Canada Corporation, IDEXX B.V., IDEXX Laboratories B.V., IDEXX Laboratories GmbH, and IDEXX Holdings II GmbH as borrowers, the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, and JPMorgan Chase Bank, N.A., Toronto Branch, as Toronto agent (which includes the Credit Agreement as Annex I).
10.2	Amended and Restated Change in Control Agreement by and between Michael (Mike) Erickson, PhD, and IDEXX Laboratories, Inc., dated January 12, 2026.
104.1		Cover Page Interactive Data File (formatted as Inline XBRL document).
10.3	Letter Agreement by and between Jonathan (Jay) Mazelsky and IDEXX Laboratories, Inc., dated January 12, 2026.
99.1	Press Release issued by IDEXX Laboratories, Inc. on January 13, 2026.
104	Cover Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IDEXX LABORATORIES, INC.	~~IDEXX LABORATORIES, INC.~~
Date: November 13, 2025	By:	/s/ Sharon E. Underberg
Date: January 13, 2026	By:	/s/ Sharon E. Underberg
	Name:	Sharon E. Underberg
		Sharon E. Underberg
	Title:	Executive Vice President, General Counsel and Corporate Secretary
		Executive Vice President, General Counsel and Corporate Secretary

Filing Compare · IDEXX LABORATORIES INC /DE